Fax: (011) 49-6221-56-5353
Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy
Article first published online: 27 APR 2007
Copyright © 2007 American Cancer Society
Volume 109, Issue 11, pages 2308–2314, 1 June 2007
How to Cite
Combs, S. E., Thilmann, C., Huber, P. E., Hoess, A., Debus, J. and Schulz-Ertner, D. (2007), Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy. Cancer, 109: 2308–2314. doi: 10.1002/cncr.22703
- Issue published online: 18 MAY 2007
- Article first published online: 27 APR 2007
- Manuscript Accepted: 14 FEB 2007
- Manuscript Revised: 5 FEB 2007
- Manuscript Received: 17 NOV 2006
- Rathke pouch;
- fractionated stereotactic radiotherapy;
- local control;
The long-term outcome in patients with craniopharyngiomas treated with fractionated stereotactic radiotherapy (FSRT) was evaluated.
A total of 40 patients with craniopharyngiomas were treated between May 1989 and July 2006 with FSRT. Most patients were treated for tumor progression after surgery. A median target dose of 52.2 grays (Gy) (range, 50.4–56 Gy) was applied in a median conventional fractionation of 5 × 1.8 Gy per week. Follow-up examinations included thorough clinical assessment as well as contrast-enhanced magnetic resonance imaging scans.
After a median follow-up of 98 months (range, 3–326 months), local control was 100% at both 5 years and 10 years. Overall survival rates at 5 years and 10 years were 97% and 89%, respectively. A complete response was observed in 4 patients and partial responses were noted in 25 patients. Eleven patients presented with stable disease during follow-up. Acute toxicity was mild in all patients. Long-term toxicity included enlargement of cysts requiring drainage 3 months after FSRT. No visual impairment, radionecrosis, or development of secondary malignancies were observed.
The long-term outcome of FSRT for craniopharyngiomas is excellent with regard to local control as well as treatment-related side effects. Cancer 2007. © 2007 American Cancer Society.